Pharmaceutical compositions and inhibitors for blocking Nsp15 endoribonuclease to treat nidovirus infections

Background

The field of antiviral therapeutics, particularly for diseases caused by nidoviruses such as coronaviruses, has gained significant attention due to the global impact of outbreaks like SARS, MERS, and COVID-19. Nidoviruses encode a set of non-structural proteins that are essential for their replication and ability to evade the host immune system. Among these, Nsp15 is an RNA uridylate-specific endoribonuclease that plays a critical role in viral RNA processing and immune evasion. The conservation of Nsp15 across various pathogenic coronaviruses makes it an attractive target for broad-spectrum antiviral drug development. The urgent need for effective treatments is underscored by the rapid emergence and spread of novel coronaviruses, the limited efficacy of existing therapies, and the ongoing threat of future pandemics.

Current approaches to treating nidovirus infections primarily focus on inhibiting viral entry, replication, or protease activity, but these strategies face several limitations. Many antiviral drugs target viral proteins that are prone to mutation, leading to the rapid development of drug resistance. Additionally, existing therapies often have limited efficacy against a broad spectrum of nidoviruses, and some may cause significant side effects or toxicity. There is also a lack of specific inhibitors that target the unique enzymatic functions of Nsp15, despite its essential role in viral replication and immune evasion. As a result, there remains a critical gap in the availability of therapeutics that can effectively and safely inhibit Nsp15 activity, reduce viral load, and mitigate disease severity across multiple nidovirus species.

Technology

This technology centers on the inhibition of the Nsp15 endoribonuclease, an enzyme crucial for the replication and immune evasion of nidoviruses, including SARS-CoV-2, MERS-CoV, and SARS-CoV. The solution comprises a suite of chemical agents—such as uridylic acids, GPU dinucleotide derivatives, tipiracil and its analogs, tetracycline antibiotics, anthracycline antineoplastic agents, and kinase inhibitors—that competitively bind to the Nsp15 active site, particularly targeting the uracil recognition pocket defined by amino acids Ser294, Tyr343, and Leu346. By blocking the enzyme’s RNA uridylate-specific endoribonuclease activity, these compounds disrupt viral RNA processing, thereby inhibiting viral replication. The technology includes detailed pharmaceutical compositions and formulations suitable for oral, parenteral, or aerosol administration, validated through structural biology (X-ray crystallography), biochemical assays, cell culture studies, and in vivo animal models.

What differentiates this technology is its comprehensive, structure-guided approach to antiviral development against a broad spectrum of nidoviruses. Unlike traditional antivirals that often target viral entry or polymerase activity, this solution exploits the unique and highly conserved Nsp15 enzyme, which is pivotal for both viral proliferation and immune evasion. The use of high-resolution crystallography to map ligand interactions enables rational drug design and optimization, while the inclusion of both novel nucleoside analogs (like GPU derivatives and tipiracil) and repurposed drugs broadens the therapeutic arsenal and accelerates translational potential. Furthermore, the platform’s versatility—encompassing multiple administration routes, detailed compound variants, and applicability to diverse respiratory and inflammatory diseases—positions it as a robust and adaptable strategy for current and future nidovirus outbreaks, including COVID-19 and related illnesses.

Benefits

• Effectively inhibits Nsp15 endoribonuclease, a key enzyme essential for nidovirus replication and immune evasion.
• Targets a broad range of nidoviruses including SARS-CoV-2, MERS-CoV, SARS-CoV, arteriviruses, and toroviruses.
• Utilizes both repurposed drugs (e.g., tetracyclines, kinase inhibitors) and novel nucleoside analogs (e.g., tipiracil, GPU dinucleotide derivatives) for antiviral activity.
• Demonstrated reduction of viral replication and spike protein expression in cell culture with low cytotoxicity.
• Supported by detailed structural insights enabling competitive inhibition at the Nsp15 active site, enhancing drug design.
• Provides versatile pharmaceutical formulations suitable for oral, parenteral, topical, and aerosol administration.
• Shows in vivo efficacy in reducing infection severity and viral load in mammals infected with nidoviruses.
• Offers a comprehensive antiviral platform with potential to treat respiratory, inflammatory, and gastrointestinal diseases caused by nidoviruses.

Applications

• COVID-19 antiviral therapeutics
• MERS and SARS treatment
• Broad-spectrum respiratory antivirals
• Veterinary nidovirus infection control

Additional info

These pharmaceutical compositions utilize agents like tipiracil and GPU dinucleotide derivatives to competitively inhibit the Nsp15 endoribonuclease in nidoviruses. By targeting the uracil recognition pocket—specifically residues Ser294, Tyr343, and Leu346—these compounds block RNA uridylate-specific activity. This mechanism disrupts viral RNA processing and immune evasion, suppressing replication of coronaviruses and arteriviruses. Formulations are designed for oral, parenteral, or aerosol administration to treat respiratory and inflammatory diseases.